Quantcast

Sagent Pharmaceuticals Announces Presentations at Upcoming Lazard Capital Markets and Piper Jaffray Healthcare Conferences

November 7, 2008

SCHAUMBURG, Ill., Nov. 7 /PRNewswire/ — Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that President and Chief Executive Officer Jeffrey M. Yordon will be presenting at two upcoming conferences. Details of Mr. Yordon’s presentations are as follows.

   November:   -- Jeffrey M. Yordon will present at the Lazard Capital Markets 5th Annual      Healthcare Conference on Wednesday, November 19 at 1:00 p.m. ET.  The      conference will host presentations from 125 leading healthcare      companies from the biotechnology, medical technology and diagnostic      device industries as well as five expert physician panel discussions.      The Lazard Capital Markets conference is being held November 18 - 19,      2008 at the St. Regis Hotel in New York, N.Y.     December:   -- Mr. Yordon will also present at the Piper Jaffray 20th Annual Health      Care Conference on Tuesday, December 2 at 11:10 a.m. ET.  This year's      Piper Jaffray conference will feature presentations from more than 180      public and private companies in biotechnology, specialty      pharmaceuticals, drug discovery, medical diagnostics and devices, and      health care services as well as panel discussions on topics of      regulatory, reimbursement and legal issues. The conference will be held      December 2 - 3, 2008 at the Palace Hotel in New York, N.Y.     About Sagent Pharmaceuticals, Inc.  

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.sagentpharma.com/.

Sagent Pharmaceuticals, Inc.

CONTACT: Investors, Ronald E. Pauli of Sagent Pharmaceuticals, Inc.,+1-847-908-1604; or Media, Aline Schimmel of WeissComm Partners,+1-312-646-6293, for Sagent Pharmaceuticals, Inc.

Web site: http://www.sagentpharma.com/




comments powered by Disqus